| 1 |
Cohort 1: hatg, csa, epag day 14 to month 6 |
Antilymphocyte immunoglobulin (horse) |
[1] D08808 D08808 💬 |
- |
- |
060 [1] 60 💬 |
| 2 |
Cohort 2: hatg, csa, epag day 14 to month 3 |
Antilymphocyte immunoglobulin (horse) |
[1] D08808 D08808 💬 |
- |
- |
060 [1] 60 💬 |
| 3 |
Cohort 3: hatg, csa (dose reduced), epag day 1 to month 6 |
Antilymphocyte immunoglobulin (horse) |
[1] D08808 D08808 💬 |
- |
- |
060 [1] 60 💬 |
| 4 |
Enalapril |
Enalapril |
[2] D00621 D00621, D07892 D07892 💬 |
ACE [1] ACE 💬 |
Chagas disease [6] Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
019 [7] 19, 46, 66, 113, 210, 222, 223 💬 |
| 5 |
Enalapril and other angiotensin converting enzyme inhibitors |
Angiotensin II |
[4] D00150 D00150, D00621 D00621, D02014 D02014, D07892 D07892 💬 |
ACE [3] ACE, AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications [18] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 [1] 19 💬 |
| 6 |
Enalapril maleate |
Enalapril |
[2] D00621 D00621, D07892 D07892 💬 |
ACE [1] ACE 💬 |
Chagas disease [6] Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
046 [1] 46 💬 |
| 7 |
Enalapril valsartan methylprednisone |
Enalapril |
[3] D00400 D00400, D00621 D00621, D07892 D07892 💬 |
ACE [2] ACE, AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications [18] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
066 [1] 66 💬 |
| 8 |
Epa |
- |
- |
- |
- |
008 [6] 8 , 46, 48, 49, 113, 301 💬 |
| 9 |
Epa and dha |
- |
- |
- |
- |
113 [1] 113 💬 |
| 10 |
Epa and dha supplementation |
- |
- |
- |
- |
048 [2] 48, 49 💬 |
| 11 |
Epadel |
- |
- |
- |
- |
296 [1] 296 💬 |
| 12 |
Epanova |
- |
- |
- |
- |
096 [1] 96 💬 |
| 13 |
Epanova™ (omega-3 free fatty acids) |
Omega-3 fatty acids |
- |
- |
- |
096 [1] 96 💬 |
| 14 |
Eparmefolin 30 cpr 0,1/0,5mg |
- |
- |
- |
- |
013 [1] 13 💬 |
| 15 |
Epatuzumab |
- |
- |
- |
- |
049 [1] 49 💬 |
| 16 |
Epax 6000 ee 1000mg (0.6 gr dha+epa) |
- |
- |
- |
- |
046 [1] 46 💬 |
| 17 |
Epaxal |
- |
- |
- |
- |
046 [1] 46 💬 |
| 18 |
Epaxal berna (virosomal hepatitis a vaccine) |
Hepatitis A Vaccine |
- |
- |
- |
096 [2] 96, 97 💬 |
| 19 |
Ethyl-epa |
Icosapent ethyl |
[1] D01892 D01892 💬 |
- |
- |
008 [1] 8 💬 |
| 20 |
Ethyl-epa (miraxion™) |
Icosapent ethyl |
[1] D01892 D01892 💬 |
- |
- |
008 [1] 8 💬 |
| 21 |
Hepatitis a vaccine ( havrix or epaxal) |
Hepatitis A Vaccine |
- |
- |
- |
046 [1] 46 💬 |
| 22 |
Over the counter dha/epa dietary supplementation |
- |
- |
- |
- |
301 [1] 301 💬 |